April 25th 2024
A retrospective study challenges preoperative withholding of GLP-1 RAs in diabetes patients undergoing surgery, citing no increased risk of postoperative respiratory complications.
FreeStyle Libre Sensors Cleared for Integration with Automated Insulin Delivery Systems
March 6th 2023The US FDA has granted clearance to the FreeStyle Libre 2 and FreeStyle Libre 3 sensors for integration with automated insulin delivery systems. Abbott, which noted ongoing collaborations with Insulet and Tandem, expects the modified sensors to be available in the US later this year.
Diabetes Community Reacts to Insulin Price Reduction by Eli Lilly and Company
March 2nd 2023After Eli Lilly and Company announced major reductions in list prices for multiple insulin products, the community rejoiced at the though of taking a major step forward toward equitable access to insulin. Learn more about the reaction from major organizations and those within the field.
Diabetes Dialogue: Practical Updates in Pediatric Diabetes, with Stuart Weinzimer, MD
March 2nd 2023In this episode, Stuart Weinzimer, MD sits down with hosts for a discussion on his research and experience with diabetes technology, the need to focus on patient-reported outcomes in pediatric diabetes, and strategies for meeting the practical needs of individuals with diabetes.
Eli Lilly and Company Announces 70% Reductions in Insulin Prices
March 1st 2023Announced on March 1, Eli Lilly and Company's reduction in insulin product list prices includes non-branded insulin lispro, Rezvoglar, KwikPens, Humulin, and Humalog. The company would also be instituting an out-of-pocket cost cap of $35 for most insulin users.
Diabetes Dialogue: Actualizing the Optimal Role of Inhaled Insulin, with Joanne Rinker, MS, RDN
February 28th 2023Hosts are joined by the associate director of Medical Affairs and Medical Education at MannKind for a special edition episode from ATTD 23 that focuses on use of inhaled insulin and future research plans for MannKind.
Diabetes Dialogue: Updates in Diabetes Management from ATTD 23, with Irl Hirsch, MD
February 26th 2023In this episode, Irl Hirsch, MD, discusses a study he is conducting examining skin changes associated with insulin pump use in people with type 1 diabetes. Later in the episode, Hirsch discusses what he is most excited about in terms of ongoing and future research in diabetes management.
Diabetes Dialogue: Screenings for Hearing Loss in Diabetes, with Joanne Rinker, MS, RDN
February 25th 2023In this episode from ATTD 2023, hosts are joined by Joanne Rinker, MS, RDN, who provides perspective on hearing loss in diabetes, including prevalence, the need for screening, and the underecognition of auditory issues in the midst of a growing population of people with diabetes.
Diabetes Dialogue: Mental Health and PRO Standardization, with Katharine Barnard-Kelly, PhD
February 25th 2023In this episode, hosts sit down with Katharine Barnard-Kelly, PhD, at ATTD 2023 to discuss the evolving recognition of the role of psychology in diabetes management for both pediatric and adult populations.
Diabetes Dialogue: Dexcom G7 and the Future of CGM, with Jake Leach
February 24th 2023At ATTD 2023, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, have an extended conversation with the new chief operating officer at Dexcom, Jake Leach, to discuss the global and US rollouts of the Dexcom G7 and what the future might hold for Dexcom.
David Maahs, MD, PhD: Leveraging Telehealth to Improve Diabetes Care
February 23rd 2023David Maahs, MD, PhD, sits down to discuss data he presented at ATTD 2023 and provide perspective on ongoing issues plaguing the diabetes community, including optimization of telehealth and addressing disparities in care.
CGM Reduces Glycemic Events, Hospitalizations in Older Adults, Regardless of Diabetes Type
February 21st 2023An analysis of Veterans Affairs data from more than 20,000 people with diabetes provides an overview of the associations of CGM initiation with improved glycemic control and reduced hospitalization in this patient population.
In Type 2 Diabetes, Low Carb Diet Linked to Lower Risk of Death from Cancer, Cardiovascular Disease
February 16th 2023Using data from a pair of major studies, investigators from the Harvard T.H. Chan School of Public Health shed new light on the impact of low-carbohydrate diet scores in people with type 2 diabetes.
Study Confirms Increased Risk of New-Onset Type 2 Diabetes After COVID-19 Infection
February 15th 2023An analysis of data from more than 20,000 adults with a documented COVID-19 infection from Los Angeles, CA has brought forth results the investigators suggest prove the association between COVID-19 infection and increased risk of type 2 diabetes, regardless of vaccination status.
Shared Decision-Making to Improve Long-Term Outcomes in Diabetes and Obesity
February 8th 2023Drs Diana Isaacs and Natalie Bellini highlight the need for engaging patients in shared decision-making and addressing social determinants of health in diabetes and obesity management in adults and pediatric patients.
Exposure to Phthalates Linked to Diabetes in Midlife Among White Women
February 8th 2023Further adding to the discussion surrounding the impact of endocrine-disrupting chemicals, an analysis of data from the SWAN Multipollutant Study suggests increased exposure to phthlates was linked to a 30-63% increase in risk of developing diabetes among White women in midlife.
Vitamin D Could Cut Risk of Progression to Type 2 Diabetes in People with Prediabetes
February 7th 2023Leveraging data from the Tromsø study, the D2d study, and the DPVD study, a systematic review and meta-analysis concluded vitamin D supplementation could help reduce risk of progression to diabetes by 15% among people with prediabetes.
In T2D, SGLT2s Provide Greater CV Risk Reduction Than DPP-4 Inhibitors
February 7th 2023A new-user comparator study of adults with type 2 diabetes indicates use of SGLT2 inhibitors was associated with a 54% lower risk of hospitalizations for heart failure and a 15% lower risk of a modified MACE outcome compared to use of DPP-4 inhibitors.